International Myeloma Foundation
MYELOMA MINUTE | Up To The Minute News | 1.6.2022
older couple in living room banner
elderly man outside his window
We Made It to 2022: What’s Next?
While we’ve struggled to get through 2020 and 2021, IMF Chairman of the Board Dr. Brian G.M. Durie advises us to approach 2022 with hope and resilience to move forward. In Dr. Durie’s own wise words: “The healing of the body starts with the healing of the mind. This positive belief will pull you forward to a future with improved health, joy, and accomplishment.”
Janssen Submits Biologics License Application to FDA Seeking Approval of Teclistamab for the Treatment of Relapsed or Refractory Multiple Myeloma Patients
On December 29, 2021, the Janssen Pharmaceutical Companies of Johnson & Johnson announced the submission of a Biologics License Application (BLA) to the U.S. Food and Drug Administration (FDA) seeking approval of teclistamab for the treatment of patients with relapsed or refractory (R/R) multiple myeloma. Teclistamab is an investigational, off-the-shelf, T-cell redirecting, bispecific antibody targeting both B-cell maturation antigen (BCMA) and CD3.
covid 19 booster shot needle
Check the Latest COVID-19 Updates and Recommendations from the IMF
With the omicron variant becoming a recent cause of concern, read up on the IMF’s latest updates and recommendations on COVID-19 vaccines and antiviral treatments for myeloma patients.
visit now button
Best of ASH 2021 Replay Banner
Watch the Replay: The Best of ASH 2021 Webinar’s Highlights and Takeaways
The Best of ASH 2021 Webinar may have come and gone, but you can still catch the replay of important takeaways and highlights of the top myeloma abstracts presented at ASH 2021, as discussed by IMF Chairman of the Board, Dr. Brian G.M. Durie.
laurie's hats fundraiser collage
Laurie’s Winter Hat Boutique: A Warm and Fuzzy Member FUNraiser for a Cause
Keep your heads snug during these chilly winter days and your hearts warm raising money for a cause with Laurie’s Winter Hat Boutique hand-knit hats! Help Laurie Hinze reach her goal — all proceeds will go to myeloma research with the International Myeloma Foundation.
blocks that spells give on hands
2022 Goal and Resolution: Start Your Own IMF Fundraiser This Year!
Is doing something meaningful for others a part of your goals and resolutions for 2022? If so, holding a myeloma fundraiser and raising public awareness in your community might just fit the bill! Whether you’re a first-timer or a veteran community fundraiser, the IMF team is here to explore event ideas and share experiences with you for a successful fundraiser. For more info, email Suzanne Battaglia, IMF Senior Director — Member Events at, or call (800) 452-2873, ext. 227.
start now button
importance of abstracts from ASH blog photo
#ASKDRDURIE | Dr. Durie's Weekly Web Video Series
How important are the four iStopMM abstracts that were presented at ASH for myeloma patients?
Watch Now
Online Patient Forum

Smart Patients: Join the Conversation
Clinical Trial Fact Sheets

CANOVA Trial (Accruing)

Phase II Relapsed or Refractory Venetoclax Trial (Accruing)

Phase I/II Trial Using a Venetoclax Combination With or Without Bortezomib (Accruing)

IKEMA Trial (Fully Accrued)

IMROZ Trial (Fully Accrued)

BOSTON Trial (Fully Accrued)
Ongoing Replays
Watch the Replay
IMWG Conference Series: ASH 2021

Watch the Replay
Advances in Myeloma Treatments Webinar

Watch the Replay
COVID-19 and Myeloma Webinar

Watch the Replay
Regional Community Workshop

See also, all of our events.

We Thank Our Sponsors:

Amgen, Bristol Myers Squibb, GSK, Karyopharm Therapeutics, Oncopeptides Inc.,
Sanofi-Genzyme, and Takeda Oncology
We also thank individuals like you for your continued support!
Subscribe Button@2x.jpg
Join the conversation at The International Myeloma Foundation
Facebook Facebook: /Myeloma  |  Twitter Twitter @IMFMyeloma  |  Instagram Instagram @IMFmyeloma
This email was sent by:
The International Myeloma Foundation
4400 Coldwater Canyon Ave., Suite 300
Studio City, CA 91604
Connect with the IMF InfoLine
We respect your privacy and your preferences for communications of this nature.
Home  •  Unsubscribe  •  Privacy Policy
View as web page